Huaxi Biotech's “influencer” transformation or what is a custom synthetic creature in the shell

“Investor Network” Cai Jun is standing in the midst of ups and downs, and Huaxi Biotech (688363.SH, hereinafter referred to as the “Company”) is probably still in the rain. In April of this year, the company announced the departure of Ma Shouwei, the former core technician. According to data, Ma Shouwei was previously the functional skincare development director at the Shanghai R&D Center, where he was mainly responsible for basic formulation technology and functional product formulation research and development. Prior to joining the company, he had experience with international brands such as Unilever and L'Oréal. Ma Shouwei's research and development field is mainly cosmetics. This is in line with the company's efforts over the past few years, which is to transform from hyaluronic acid raw materials to a cosmetics company. However, the company said goodbye in 2023

China InvestorsApr 9 07:31

Huaxi Biotech (688363.SH): spent 204 million yuan to repurchase a total of 3.0402 million shares

Gelonghui, April 1, 丨 Huaxi Biotech (688363.SH) announced that as of March 31, 2024, the company had repurchased a total of 3,0402 million shares through the Shanghai Stock Exchange trading system, accounting for 0.6312% of the company's total share capital. The highest price of the repurchase transaction was 89.71 yuan/share, the lowest price was 56.90 yuan/share, and the total amount of capital paid was RMB 204 million (excluding transaction fees such as stamp duty and transaction fees).

Gelonghui FinanceApr 1 18:52

Express News | Huaxi Biotech invests in the establishment of a management consulting company with businesses related to artificial intelligence

BreakingsMar 28 10:16

Express News | Huaxi Biotech Beijing invests in the establishment of a new company including health food sales business

BreakingsMar 22 09:50

Bloomage BioTechnology Corporation Limited's (SHSE:688363) Last Week's 3.6% Decline Must Have Disappointed Private Equity Firms Who Have a Significant Stake

Key Insights Bloomage BioTechnology's significant private equity firms ownership suggests that the key decisions are influenced by shareholders from the larger public The largest shareholder of the

Simply Wall StMar 20 06:20

Huaxi Biotech (688363.SH): A total of 2.71 million shares were repurchased at a cost of 183 million yuan

Gelonghui, March 5, 丨 Huaxi Biotech (688363.SH) announced that as of February 29, 2024, the company had repurchased 2.71 million shares of the company's shares through centralized bidding transactions, accounting for 0.5626% of the company's total share capital of 481,678,242 shares. The highest price of the repurchase transaction was 89.71 yuan/share, the lowest price was 56.90 yuan/share, and the total amount of capital paid was RMB 183 million (excluding transaction fees such as stamp duty and transaction fees).

Gelonghui FinanceMar 5 17:17